For research use only. Not for therapeutic Use.
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1)[1][1].
| Catalog Number | I045039 |
| CAS Number | 1303512-02-8 |
| Synonyms | tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate |
| Molecular Formula | C22H28ClN3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H28ClN3O4/c1-22(2,3)30-21(29)25-12-10-24(11-13-25)15-17-8-9-26(20(28)19(17)27)14-16-4-6-18(23)7-5-16/h4-9,27H,10-15H2,1-3H3 |
| InChIKey | UPJZLOCUUOIMNC-UHFFFAOYSA-N |
| SMILES | CC(C)(C)OC(=O)N1CCN(CC1)CC2=C(C(=O)N(C=C2)CC3=CC=C(C=C3)Cl)O |
| Reference | [1]. Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. [2]. Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1. |
